BioCentury | Oct 31, 2013
Distillery Therapeutics

Indication: Dermatology

Indication Target/marker/pathway Summary Licensing status Publication and contact information Dermatology Wounds Myocardin-related transcription factor A (MKL1; MAL; MRTF-A) Mouse studies suggest MRTF-A activation could help treat dermal wounds. In mice with dermal wounds, local application...
BioCentury | Mar 21, 2013
Targets & Mechanisms

Understanding fibrosis

Researchers at The University of Alabama at Birmingham have identified idiopathic pulmonary fibrosis as a repurposing opportunity for fasudil, a Rho kinase inhibitor that Asahi Kasei Pharma Corp. markets as Eril to treat aneurysm. The...
BioCentury | Mar 14, 2013
Distillery Therapeutics

Indication: Pulmonary disease

Indication Target/marker/pathway Summary Licensing status Publication and contact information Pulmonary disease Pulmonary fibrosis Rho kinase; myocardin-related transcription factor A (MKL1; MAL; MRTF-1) Human tissue and mouse studies suggest inhibiting Rho kinase or MKL1 could help...
BioCentury | May 12, 2011
Distillery Techniques

Technology: Drug platforms

This week in techniques Approach Summary Licensing status Publication and contact information Drug platforms Adjuvant combination for increased influenza vaccine efficacy Combining the adjuvants alum and monophosphoryl lipid A (MPL) could help improve influenza vaccine...
BioCentury | Apr 2, 2009
Distillery Therapeutics

Indication: Cancer

This week in therapeutics Indication Target/marker/pathway Summary Licensing status Publication and contact information Cancer Acute megakaryoblastic leukemia (AMKL) One twenty-two protein (RBM15; OTT); megakaryocytic acute leukemia (MKL1; MAL); myeloproliferative leukemia virus oncogene (MPL); recombination signal...
Items per page:
1 - 5 of 5